Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.52 |
| ▸ | RXRB | P28702 | 3/20 | 0.52 |
| ▸ | RXRG | P48443 | 3/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79041 | 0.85 | RXRA (0.56) | RXRARXRBRXRGMRGPRX4S1PR1 | |
| SCHEMBL6812974 | 0.82 | CYP4F2 (0.54) | RXRARXRBRXRGMRGPRX4S1PR1 | |
| SCHEMBL18924486 | 0.82 | RXRA (0.50) | RXRARXRBRXRGMRGPRX4S1PR1 | |
| SCHEMBL20756090 | 0.82 | RXRA (0.54) | RXRARXRBRXRGMRGPRX4CTSS | |
| SCHEMBL86405 | 0.81 | RXRA (0.49) | RXRARXRBRXRGMRGPRX4S1PR1 | |
| SCHEMBL27806830 | 0.81 | RXRA (0.46) | RXRARXRBRXRGMRGPRX4S1PR1 | |
| SCHEMBL932578 | 0.81 | RXRA (0.40) | RXRARXRBRXRGMRGPRX4S1PR1 | |
| SCHEMBL2074825 | 0.80 | SLC2A1 (0.52) | SLC6A4FOLH1 | |
| SCHEMBL14453588 | 0.80 | MRGPRX4 (0.50) | RXRARXRBRXRGMRGPRX4S1PR1 | |
| SCHEMBL3726426 | 0.80 | PTGER1 (0.54) | RXRARXRBRXRGMRGPRX4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| CN-101730677-B | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORP | 2014-07-16 | — | — | CN | disclosed |
| EP-1446388-B1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | STERIX LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| EP-1446388-B1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | STERIX LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| US-7361677-B2 | Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase | STERIX, LTD. (GB) | 2008-04-22 | — | — | US | disclosed |
| US-7361677-B2 | Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase | STERIX, LTD. (GB) | 2008-04-22 | — | — | US | disclosed |
| US-7361677-B2 | Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase | STERIX, LTD. (GB) | 2008-04-22 | — | — | US | disclosed |
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STERIX LTD. | 2006-10-26 | — | — | US | disclosed |
| US-7098343-B2 | Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor | STERIX, LIMITED (GB) | 2006-08-29 | — | — | US | disclosed |
| US-20060142360-A1 | Compound | RICHTER GEDEON NYRT. (HU) | 2006-06-29 | — | — | US | disclosed |
| CN-1599728-A | Sulfamate-containing 1,2, 4-triazole derivatives as aromatase inhibitors | STERIX LTD (GB) | 2005-03-23 | — | — | CN | disclosed |
| EP-1446388-A1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | Sterix Limited (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20040019016-A1 | Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor | RICHTER GEDEON NYRT. (HU) | 2004-01-29 | — | — | US | disclosed |
| WO-2003045925-A1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | STERIX LIMITED (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STS, SULT1E1, CYP19A1 | RXRA 2518/4885RXRB 2305/4885RXRG 2300/4885 |
| US-20060142360-A1 | Compound | QPCT, SQOR, SDHA | RXRA 1453/4885RXRB 1128/4885RXRG 1041/4885 |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | HRH3, HRH2, HRH4 | RXRA 2471/4885RXRB 2398/4885RXRG 2190/4885 |
| US-20040019016-A1 | Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor | STS, CYP21A2, SULT1E1 | RXRA 2296/4885RXRB 2073/4885RXRG 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.